DOCSLIB.ORG

Transcortin: a Corticosteroid-Binding Protein of Plasma. VII. Half-Life in Normal and Estrogen-Treated Subjects

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Transcortin: a Corticosteroid-Binding Protein of Plasma. VII. Half-Life in Normal and Estrogen-Treated Subjects Transcortin: A Corticosteroid-binding Protein of Plasma. VII. Half-Life in Normal and Estrogen-treated Subjects Avery A. Sandberg, … , S. Nienhouse, W. R. Slaunwhite Jr. J Clin Invest. 1964;43(3):461-466. https://doi.org/10.1172/JCI104931. Research Article Find the latest version: https://jci.me/104931/pdf Journal of Clinical Investigation Vol. 43, No. 3, 1964 Transcortin: A Corticosteroid-binding Protein of Plasma. VII. Half-Life in Normal and Estrogen-treated Subjects * AVERY A. SANDBERG, M. WOODRUFF, H. ROSENTHAL, S. NIENHOUSE, AND W. R. SLAUNWHITE, JR. (From the Roswell Park Memorial Institute, Buffalo, N. Y.) In 1959 we described elevated plasma concen- The present study was undertaken to deter- trations of transcortin during pregnancy and after mine whether the elevated transcortin levels fol- the administration of estrogens (1, 2). Since lowing estrogen therapy are due 1) to increased then, a number of investigations utilizing a va- synthesis of the protein or 2) to decreased turn- riety of methodologies to ascertain the binding over and, hence, prolonged half-life of transcortin. of cortisol to transcortin have confirmed our ob- This study has been made feasible through the servations (3-8). The different techniques used isolation by Seal and Doe (9, 10) of a highly and the diverse arithmetic approaches employed purified and well-characterized preparation of all indicate that the plasma concentration of trans- transcortin, making possible the injection of la- cortin rises about threefold during pregnancy or beled transcortin free from any significant pro- after estrogen therapy. These findings (3-8) tein contaminants. Another important advance are in essential agreement with our original, less that encouraged us to undertake the study has sophisticated observations and calculations. An been the feasibility of utilizing labeled proteins important contribution has been the isolation by in the study of their half-lives and the demon- Seal and Doe (9, 10) of a highly purified plasma stration that the introduction of a small number transcortin preparation, making it possible to as- of iodine atoms into a protein appears not to certain the amino acid composition of the protein change its biological behavior (11-15). and many of its physical properties. They have shown that transcortin has one binding site for Materials and Methods cortisol and a molecular weight of approximately The transcortin used in this study was isolated ac- 45,000 (9, 10). More recently, these workers cording to the method of Seal and Doe (9, 10).1 The have demonstrated, by means of isolation studies, protein was iodinated according to the technique of that the plasma transcortin concentration is ap- Pressman and Eisen (16) as modified by Day, Planinsek, 100 ml in normal sub- Korngold, and Pressman (17). The iodination proce- proximately 2.5 mg per dures described below were standardized many times jects and 7.5 mg per 100 ml in estrogen-treated in our laboratory utilizing various proteins (17). The subjects (7). These and other values for nor- iodination of the transcortin was carried out on the morn- mal, estrogen-treated, and pregnant subjects (3-8) ing when the subjects were injected. Since we did not are higher than our original calculations (1). know the length of time during which the plasma would can have to be sampled, I"25 was chosen because its half-life Our low values be attributed to the crudeness is greater than that of 181. The results indicate that of the early techniques and the less critical theo- I1" could have served as well. retical physicochemical approaches utilized. The The iodide in 266 ,uc of ,KIJu (carrier free) and 80 methods used in our laboratory now obviate these A1l of 0.0025 M KI was oxidized by the addition of 0.1 shortcomings and yield values similar to those ob- ml of 1 N HCl and 0.05 ml of 0.02 M NaNO,. The tained other workers. pH was immediately made slightly alkaline by adding by 0.5 ml of a 1: 4 (vol/vol) mixture of 1 N NaOH and M * 0.167 borate buffer (pH 7.9) in 0.133 M NaCl. The Submitted for publication September 19, 1963; ac- alkaline iodine solution was added to 3.0 mg of trans- cepted November 14, 1963. cortin dissolved in 0.6 ml of water. The reaction mix- This study has been supported in part by grant A-1240 from the National Institute of Metabolic and 1The transcortin was kindly supplied by Dr. U.. S. Endocrine Disorders, U. S. Public Health Service. Seal. 461 462 SANDBERG, WOODRUFF, ROSENTHAL, NIENHOUSE, AND SLAUNWHITE ture was immediately passed through a 4- X 40-mm col- dogenous transcortin. Radioactive iodine and carbon umn of Amberlite IR-4B (OH) anion exchange resin were assayed simultaneously in a dual chainel liquid (analytical grade) to remove iodide ion. At this step, scintillation spectrometer in a dioxane-ethoxyethanol 22% of the I'2' reacted with transcortin. After passage solvent (20). The degree of correlation of the two through another column of IR-4B resin to ensure com- isotopes was taken as a measure of the identity of ex- plete removal of iodide, the iodination yield was 16%, ogenous I126-transcortin with the endogenous protein. which was equivalent to 0.4 atoms of iodine per mole The chromatography was performed at 4° as follows. of transcortin. This solution was diluted to 250 ml with Approximately 30 ml of plasma was dialyzed overnight physiological saline. against 10 vol of distilled water. The pH of the plasma Treatment of two patients with carcinoma of the was adjusted to 5.0, and the plasma was centrifuged. prostate with diethylstilbestrol (15 mg per day) was The supernatant liquid was applied to a 2- X 30-cm initiated 2 weeks before the injection of 1125-transcortin column of DEAEC equilibrated with buffer, which was and continued throughout the experimental period. 0.025 M in NaCl and 0.015 M in NaH.PO at pH 5.0. Three male laboratory personnel served as untreated After the plasma had percolated into the resin, 0.1 Ac of controls. Just before the injection of IY5-transcortin, 4-C4-cortisol(_0 ,uc per mg) in buffer was added. 30 ml of blood was drawn in heparin. The saline solu- Elution with the same buffer was commenced and con- tion of I'-transcortin (50 ml) was injected intrave- tinued until the optical density at 280 mA of the effluent nously over a period of 1 to 3 minutes. At periodic in- was between 0.2 and 0.6. At this point most of the al- tervals small (10-ml) samples of blood from an oppo- bumin and its associated yellow pigment had been eluted, site arm vein were withdrawn for assay of radioactivity. but the blue band due to ceruloplasmin was at the top of At 1 hour and at 9 days after injection, 50-ml samples the column. A gradient in ionic strength at a con- of blood were drawn, and chromatography of the plasma stant pH of 5.0 was started, using 800 ml of the initial from these samples was performed. buffer in a mixing chamber and dropping inito it a buffer Determination of traniscortin concentration. Plasma consisting of 1: 9 (vol/vol) 0.2 M NaH?PO: 0.09 M cortisol determinations were performed according to NaCl at pH 5.0. Fractions of 30 ml in volume were col- the method of Plager, Cushman, and Chase (18) on lected at a flow rate of less than 1 ml per minute until the preinjection sample of plasma. Equilibrium dialyses the blue band had passed out of the column. were performed at various concentrations of cortisol The protein concentration of each fraction was de- as previously described (1), both before and after heat- termined by comparison with an ovalbumin standard ing at 60° for 20 minutes (4). The protein concen- using the absorption band at 280 m,u. The amount of tration was determined with a Scatchard type plot (19), I125 and C4 in 1 ml of every other fraction was deter- plotting the ratio of the percentage of unbound versus mined in a dual channel liquid scintillation spectrometer. the concentration of bound cortisol. Our experience The high voltage and discriminator were set so that (1), as well as that of others (5, 10), has shown that 90% of the I125 counts appeared in the lower channel and the equilibrium constant of association does not change 42.5% in the upper channel. Under these conditions the with estrogen stimulation, that is, estrogen stimulation efficiency of counting (using both channels) of J125 was produces more transcortin rather than a different pro- 78%o; that of C4 was 86%. Binding of C14-cortisol was tein. Our data, after subtraction of albumin binding performed by equilibrium dialysis (1) on a suitably of cortisol, yield a value of 1 x 10'M' for the equi- diluted sample so that the percentage bound fell between librium constant of association. Using this value, and 40 and 60. The percentage bound per milligram of pro- a molecular weight of 45,000 for the corticosteroid- tein was then calculated. Unless all determinations are binding protein, the concentration of transcortin binding brought to the same end-point (not necessarily this one), sites was calculated for each plasma. Since Seal and comparisons are invalid (19). Doe (9, 10) have shown that there is only one binding site on transcortin for cortisol, this value is also the Results concentration of transcortin. Determination of the half-life of transcortint. From All the subjects were injected between 10 a.m. each specimen, 1 or 2 ml of whole blood was removed and 12 noon and (except normal subject R.E.) for counting.
Load more

Recommended publications
  • Types of Acute Phase Reactants and Their Importance in Vaccination (Review)
    BIOMEDICAL REPORTS 12: 143-152, 2020 Types of acute phase reactants and their importance in vaccination (Review) RAFAAT H. KHALIL1 and NABIL AL-HUMADI2 1Department of Biology, College of Science and Technology, Florida Agricultural and Mechanical University, Tallahassee, FL 32307; 2Office of Vaccines, Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD 20993, USA Received May 10, 2019; Accepted November 25, 2019 DOI: 10.3892/br.2020.1276 Abstract. Vaccines are considered to be one of the most human and veterinary medicine. Proteins which are expressed cost-effective life-saving interventions in human history. in the acute phase are potential biomarkers for the diagnosis The body's inflammatory response to vaccines has both of inflammatory disease, for example, acute phase proteins desired effects (immune response), undesired effects [(acute (APPs) are indicators of successful organ transplantation phase reactions (APRs)] and trade‑offs. Trade‑offs are and can be used to predict the ameliorative effect of cancer more potent immune responses which may be potentially therapy (1,2). APPs are primarily synthesized in hepatocytes. difficult to separate from potent acute phase reactions. The acute phase response is a spontaneous reaction triggered Thus, studying acute phase proteins (APPs) during vaccina- by disrupted homeostasis resulting from environmental distur- tion may aid our understanding of APRs and homeostatic bances (3). Acute phase reactions (APRs) usually stabilize changes which can result from inflammatory responses. quickly, after recovering from a disruption to homeostasis Depending on the severity of the response in humans, these within a few days to weeks; however, APPs expression levels reactions can be classified as major, moderate or minor.
    [Show full text]
  • Pleiotropic Effects of Antithrombin Strand 1C Substitution Mutations
    Pleiotropic effects of antithrombin strand 1C substitution mutations. D A Lane, … , E Thompson, G Sas J Clin Invest. 1992;90(6):2422-2433. https://doi.org/10.1172/JCI116133. Research Article Six different substitution mutations were identified in four different amino acid residues of antithrombin strand 1C and the polypeptide leading into strand 4B (F402S, F402C, F402L, A404T, N405K, and P407T), and are responsible for functional antithrombin deficiency in seven independently ascertained kindreds (Rosny, Torino, Maisons-Laffitte, Paris 3, La Rochelle, Budapest 5, and Oslo) affected by venous thromboembolic disease. In all seven families, variant antithrombins with heparin-binding abnormalities were detected by crossed immunoelectrophoresis, and in six of the kindreds there was a reduced antigen concentration of plasma antithrombin. Two of the variant antithrombins, Rosny and Torino, were purified by heparin-Sepharose and immunoaffinity chromatography, and shown to have greatly reduced heparin cofactor and progressive inhibitor activities in vitro. The defective interactions of these mutants with thrombin may result from proximity of s1C to the reactive site, while reduced circulating levels may be related to s1C proximity to highly conserved internal beta strands, which contain elements proposed to influence serpin turnover and intracellular degradation. In contrast, s1C is spatially distant to the positively charged surface which forms the heparin binding site of antithrombin; altered heparin binding properties of s1C variants may therefore reflect conformational linkage between the reactive site and heparin binding regions of the molecule. This work demonstrates that point mutations in and immediately adjacent to strand 1C have multiple, or pleiotropic, […] Find the latest version: https://jci.me/116133/pdf Pleiotropic Effects of Antithrombin Strand 1C Substitution Mutations David A.
    [Show full text]
  • COMMENTARY Possible New Mechanism of Cortisol Action In
    211 COMMENTARY Possible new mechanism of cortisol action in female reproductive organs: physiological implications of the free hormone hypothesis C Yding Andersen Laboratory of Reproductive Biology, Section 5712, University Hospital of Copenhagen, DK-2100 Copenhagen, Denmark (Requests for offprints should be addressed to C Yding Andersen; Email: [email protected]) Abstract The so-called free hormone hypothesis predicts that the cortisol to cortisone, while 11-HSD type 1 reverses this biological activity of a given steroid correlates with the free reaction. As a result, a high concentration of cortisol protein-unbound concentration rather than with the total available for biological action is present in the preovulatory concentration (i.e. free plus protein-bound). Cortisol is a follicle just prior to ovulation and it has been suggested that glucocorticoid with many diverse functions and the free cortisol may function to reduce the inflammatory-like hormone hypothesis seems to apply well to the observed reactions occurring in connection with ovulation. effects of cortisol. The ovaries express glucocorticoid This paper suggests (1) that the function of the oviduct receptors and are affected by cortisol, but lack the neces- is also affected by the high levels of free cortisol released in sary enzymes for cortisol synthesis. Ovarian follicles modu- preovulatory follicular fluid at ovulation and (2) that late the biological activity of cortisol by (1) follicular formation and function of the corpus luteum benefits from production of especially progesterone and 17-hydroxy- a high local concentration of free cortisol, whereas the progesterone which, within the follicle, reach levels that surrounding developing follicles may experience negative displace cortisol from its binding proteins, in particular, effects.
    [Show full text]
  • Differential Expressions of Plasma Proteins in Systemic Lupus
    Journal of Microbiology, Immunology and Infection (2019) 52, 816e826 Available online at www.sciencedirect.com ScienceDirect journal homepage: www.e-jmii.com Original Article Differential expressions of plasma proteins in systemic lupus erythematosus patients identified by proteomic analysis Rashmi Madda a,1, Shih-Chang Lin a,b,c,1, Wei-Hsin Sun a,**, Shir-Ly Huang d,* a Department of Life Sciences, National Central University, Taiwan b Department of Medicine, College of Medicine, Fu-Jen Catholic University, Taiwan c Division of Rheumatology and Immunology, Cathay General Hospital, Taiwan d Institute of Microbiology and Immunology, National Yang-Ming University, Taiwan Received 27 September 2017; received in revised form 18 January 2018; accepted 21 February 2018 Available online 29 March 2018 KEYWORDS Abstract Introduction: Systemic lupus erythematosus (SLE) is a chronic and complex autoim- Systemic lupus mune disease with a wide range of clinical manifestations that affects multiple organs and tis- erythematosus; sues. Therefore the differential expression of proteins in the serum/plasma have potential Biomarkers; clinical applications when treating SLE. Plasma proteins; Methods: We have compared the plasma/serum protein expression patterns of nineteen active LC-ESI-MS/MS; SLE patients with those of twelve age-matched and gender-matched healthy controls by pro- Lupus: 2D-gel teomic analysis. To investigate the differentially expressed proteins among SLE and controls, a electrophoresis; 2-dimensional gel electrophoresis coupled with high-resolution liquid chromatography tandem Proteomic analysis mass spectrometry was performed. To further understand the molecular and biological func- tions of the identified proteins, PANTHER and Gene Ontology (GO) analyses were employed. Results: A total of 14 significantly expressed (p < 0.05, p < 0.01) proteins were identified, and of these nine were up-regulated and five down-regulated in the SLE patients.
    [Show full text]
  • Part I Biopharmaceuticals
    1 Part I Biopharmaceuticals Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 3 1 Analogs and Antagonists of Male Sex Hormones Robert W. Brueggemeier The Ohio State University, Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Columbus, Ohio 43210, USA 1Introduction6 2 Historical 6 3 Endogenous Male Sex Hormones 7 3.1 Occurrence and Physiological Roles 7 3.2 Biosynthesis 8 3.3 Absorption and Distribution 12 3.4 Metabolism 13 3.4.1 Reductive Metabolism 14 3.4.2 Oxidative Metabolism 17 3.5 Mechanism of Action 19 4 Synthetic Androgens 24 4.1 Current Drugs on the Market 24 4.2 Therapeutic Uses and Bioassays 25 4.3 Structure–Activity Relationships for Steroidal Androgens 26 4.3.1 Early Modifications 26 4.3.2 Methylated Derivatives 26 4.3.3 Ester Derivatives 27 4.3.4 Halo Derivatives 27 4.3.5 Other Androgen Derivatives 28 4.3.6 Summary of Structure–Activity Relationships of Steroidal Androgens 28 4.4 Nonsteroidal Androgens, Selective Androgen Receptor Modulators (SARMs) 30 4.5 Absorption, Distribution, and Metabolism 31 4.6 Toxicities 32 Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 4 Analogs and Antagonists of Male Sex Hormones 5 Anabolic Agents 32 5.1 Current Drugs on the Market 32 5.2 Therapeutic Uses and Bioassays
    [Show full text]
  • Ceruloplasmin
    CERULOPLASMIN OSR6164 4 x 18 mL R1 4 x 5 mL R2 Intended Use System reagent for the quantitative determination of Ceruloplasmin (CER) in human serum on Beckman Coulter AU analyzers. Summary Ceruloplasmin is the primary copper containing protein in plasma. It is a late acute phase reactant synthesized by the liver. Acute phase reactant refers to proteins whose serum concentrations rise significantly during acute inflammation due to causes including surgery, myocardial infarction, infections and tumours. Ceruloplasmin’s main clinical importance is in the diagnosis of Wilson’s disease. Here plasma Ceruloplasmin concentration is reduced while dialyzable copper concentration is increased. Increased ceruloplasmin levels are particularly notable in diseases of the reticuloendothelial system such as Hodgkin’s disease as well as during pregnancy or the use of contraceptive pills. Low plasma levels of 1,2 ceruloplasmin are found in malnutrition, malabsorption, nephrosis and severe liver disease, particularly biliary cirrhosis. Methodology Immune complexes formed in solution scatter light in proportion to their size, shape and concentration. Turbidimeters measure the reduction of incident light due to reflection, absorption, or scatter. In the procedure, the measurement of the decrease in light transmitted (increase in absorbance) through particles suspended in solution as a result of complexes formed during the antigen-antibody reaction, is the basis of this assay. System Information For AU400/400e/480, AU600/640/640e/680 and AU2700/5400 Beckman Coulter Analyzers. Reagents Final concentration of reactive ingredients: Solution of Polymers in Phosphate Buffered Saline (pH 7.4 – 7.6) Rabbit anti-human Ceruloplasmin antiserum Also contains preservatives. Precautions 1. For in vitro diagnostic use.
    [Show full text]
  • The Plasmin–Antiplasmin System: Structural and Functional Aspects
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Bern Open Repository and Information System (BORIS) Cell. Mol. Life Sci. (2011) 68:785–801 DOI 10.1007/s00018-010-0566-5 Cellular and Molecular Life Sciences REVIEW The plasmin–antiplasmin system: structural and functional aspects Johann Schaller • Simon S. Gerber Received: 13 April 2010 / Revised: 3 September 2010 / Accepted: 12 October 2010 / Published online: 7 December 2010 Ó Springer Basel AG 2010 Abstract The plasmin–antiplasmin system plays a key Plasminogen activator inhibitors Á a2-Macroglobulin Á role in blood coagulation and fibrinolysis. Plasmin and Multidomain serine proteases a2-antiplasmin are primarily responsible for a controlled and regulated dissolution of the fibrin polymers into solu- Abbreviations ble fragments. However, besides plasmin(ogen) and A2PI a2-Antiplasmin, a2-Plasmin inhibitor a2-antiplasmin the system contains a series of specific CHO Carbohydrate activators and inhibitors. The main physiological activators EGF-like Epidermal growth factor-like of plasminogen are tissue-type plasminogen activator, FN1 Fibronectin type I which is mainly involved in the dissolution of the fibrin K Kringle polymers by plasmin, and urokinase-type plasminogen LBS Lysine binding site activator, which is primarily responsible for the generation LMW Low molecular weight of plasmin activity in the intercellular space. Both activa- a2M a2-Macroglobulin tors are multidomain serine proteases. Besides the main NTP N-terminal peptide of Pgn physiological inhibitor a2-antiplasmin, the plasmin–anti- PAI-1, -2 Plasminogen activator inhibitor 1, 2 plasmin system is also regulated by the general protease Pgn Plasminogen inhibitor a2-macroglobulin, a member of the protease Plm Plasmin inhibitor I39 family.
    [Show full text]
  • PROMETRIUM® (Progesterone, USP) Capsules 200 Mg WARNING
    PROMETRIUM® (progesterone, USP) Capsules 100 mg Capsules 200 mg WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER AND PROBABLE DEMENTIA FOR ESTROGEN PLUS PROGESTIN THERAPY Cardiovascular Disorders and Probable Dementia Estrogens plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia. (See CLINICAL STUDIES and WARNINGS, Cardiovascular disorders and Probable dementia.) The Women's Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of deep vein thrombosis, pulmonary embolism, stroke and myocardial infarction in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg] combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo. (See CLINICAL STUDIES and WARNINGS, Cardiovascular disorders.) The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women. (See CLINICAL STUDIES and WARNINGS, Probable dementia and PRECAUTIONS, Geriatric Use.) Breast Cancer The WHI estrogen plus progestin substudy also demonstrated an increased risk of invasive breast cancer. (See CLINICAL STUDIES and WARNINGS, Malignant neoplasms, Breast Cancer.) In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA, and other combinations and dosage forms of estrogens and progestins. Progestins with estrogens should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.
    [Show full text]
  • Antiplasmin the Main Plasmin Inhibitor in Blood Plasma
    1 From Department of Surgical Sciences, Division of Clinical Chemistry and Blood Coagu- lation, Karolinska University Hospital, Karolinska Institutet, S-171 76 Stockholm, Sweden ANTIPLASMIN THE MAIN PLASMIN INHIBITOR IN BLOOD PLASMA Studies on Structure-Function Relationships Haiyao Wang Stockholm 2005 2 ABSTRACT ANTIPLASMIN THE MAIN PLASMIN INHIBITOR IN BLOOD PLASMA Studies on Structure-Function Relationships Haiyao Wang Department of Surgical Sciences, Division of Clinical Chemistry and Blood Coagulation, Karo- linska University Hospital, Karolinska Institute, S-171 76 Stockholm, Sweden Antiplasmin is an important regulator of the fibrinolytic system. It inactivates plasmin very rapidly. The reaction between plasmin and antiplasmin occurs in several steps: first a lysine- binding site in plasmin interacts with a complementary site in antiplasmin. Then, an interac- tion occurs between the substrate-binding pocket in the plasmin active site and the scissile peptide bond in the RCL of antiplasmin. Subsequently, peptide bond cleavage occurs and a stable acyl-enzyme complex is formed. It has been accepted that the COOH-terminal lysine residue in antiplasmin is responsible for its interaction with the plasmin lysine-binding sites. In order to identify these structures, we constructed single-site mutants of charged amino ac- ids in the COOH-terminal portion of antiplasmin. We found that modification of the COOH- terminal residue, Lys452, did not change the activity or the kinetic properties significantly, suggesting that Lys452 is not involved in the lysine-binding site mediated interaction between plasmin and antiplasmin. On the other hand, modification of Lys436 to Glu decreased the reaction rate significantly, suggesting this residue to have a key function in this interaction.
    [Show full text]
  • Oral Contraceptives and Endocrine Changes* 0
    Bull. Org. mond. Sante 1972, 46, 443-450 Bull. Wid HIth Org. Oral contraceptives and endocrine changes* 0. J. LUCIS1 & R. LUCIS In groups of women taking oral contraceptives and in control groups ofwomen, the serum levels ofcortisol, protein-bound iodine, and total thyroxine were measured together with the T3 binding index. The daily excretion in the urine offree cortisol, 17-hydroxycorticoste- roids, 17-ketosteroids, pregnanediol, pregnanetriol, total oestrogens, total catecholamines, and 4-hydroxy-3-methoxymandelic acid was also assayed. The frequency distribution of the values obtained indicates that oral contraceptives have a marked influence on the endocrine environment. The smallest deviations were observed in urinary excretion of total catecholamines and of 4-hydroxy-3-methoxymandelic acid. In some individuals the hor- mone assays were continued throughout the menstrual cycle. The morning and afternoon levels of serum cortisol tended to increase during the period when the oral contraceptive was being taken. According to the estimates of the Advisory Com- to prescription, and had been doing so for at least mittee on Obstetrics and Gynecology (1969) of the 2 months. The types of oral contraceptive prepara- United States Food and Drug Administration, tions taken are shown in Table 1. 18.5 million women are using oral contraceptives. The urinary excretion of hormones and their The hormonal balance in these women may show metabolites was determined on 24-hour urine spe- deviations from that seen in normally menstruating cimens. The quantity of free cortisol in the urine was women and this problem was investigated in our assayed by the method of protein displacement bind- laboratory in order to establish the values for com- ing (Murphy, 1967) using newborn calf serum and monly used endocrine assays in women with spon- corticosterone-3H as reagents.
    [Show full text]
  • Ceruloplasmin and Hypoferremia: Studies in Burn and Non-Burn Trauma Patients
    Antioxidants 2015, 4, 153-169; doi:10.3390/antiox4010153 OPEN ACCESS antioxidants ISSN 2076-3921 www.mdpi.com/journal/antioxidants Article Ceruloplasmin and Hypoferremia: Studies in Burn and Non-Burn Trauma Patients Michael A. Dubick 1,*, Johnny L. Barr 1, Carl L. Keen 2 and James L. Atkins 3 1 U.S. Army Institute of Surgical Research, 3698 Chambers Pass, JBSA Fort Sam Houston, TX 78234, USA; E-Mail: [email protected] 2 Departments of Nutrition and Internal Medicine, University of California, Davis, CA 95616, USA; E-Mail: [email protected] 3 Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-210-539-3680. Academic Editor: Nikolai V. Gorbunov Received: 26 November 2014 / Accepted: 28 February 2015 / Published: 6 March 2015 Abstract: Objective: Normal iron handling appears to be disrupted in critically ill patients leading to hypoferremia that may contribute to systemic inflammation. Ceruloplasmin (Cp), an acute phase reactant protein that can convert ferrous iron to its less reactive ferric form facilitating binding to ferritin, has ferroxidase activity that is important to iron handling. Genetic absence of Cp decreases iron export resulting in iron accumulation in many organs. The objective of this study was to characterize iron metabolism and Cp activity in burn and non-burn trauma patients to determine if changes in Cp activity are a potential contributor to the observed hypoferremia. Material and Methods: Under Brooke Army Medical Center Institutional Review Board approved protocols, serum or plasma was collected from burn and non-burn trauma patients on admission to the ICU and at times up to 14 days and measured for indices of iron status, Cp protein and oxidase activity and cytokines.
    [Show full text]
  • Summary of Product Characteristics
    Prednisolone, DK/H/2488/001-006, March 2021 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT /…/ 2.5 mg tablets /…/ 5 mg tablets /…/ 10 mg tablets /…/ 20 mg tablets /…/ 25 mg tablets /…/ 30 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 2.5 mg prednisolone. Each tablet contains 5 mg prednisolone. Each tablet contains 10 mg prednisolone. Each tablet contains 20 mg prednisolone. Each tablet contains 25 mg prednisolone. Each tablet contains 30 mg prednisolone. Excipient with known effect: Each 2.5 mg tablet contains 89.2 mg of lactose monohydrate Each 5 mg tablet contains 87.2 mg of lactose monohydrate Each 10 mg tablet contains 81.7 mg of lactose monohydrate Each 20 mg tablet contains 163.4 mg of lactose monohydrate Each 25 mg tablet contains 159.4 mg of lactose monohydrate Each 30 mg tablet contains 153.4 mg of lactose monohydrate For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablets 2.5mg tablet Yellow, 7mm, round, flat, tablet, with a score line on one side, imprinted with “A610” on one side and “2.5” on the other. 5mg tablet White, 7mm, round, flat, tablet, with a score line on one side, imprinted with “A620” on one side and “5” on the other. 10mg tablet Red, 7mm, round, flat, tablet, with a score line on one side, imprinted with “A630” on one side and “10” on the other. 20mg tablet Red, 9mm, round, flat, tablet, with a score line on one side, imprinted with “A640” on one side and “20” on the other.
    [Show full text]